Compare GIL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIL | BMRN |
|---|---|---|
| Founded | 1946 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.0B |
| IPO Year | 1999 | 1999 |
| Metric | GIL | BMRN |
|---|---|---|
| Price | $71.19 | $63.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $75.25 | ★ $90.10 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 01-01-0001 | 04-22-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ 154.02 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $7.50 | $13.53 |
| Revenue Next Year | $100.40 | $10.40 |
| P/E Ratio | ★ $23.11 | $31.09 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $39.28 | $50.76 |
| 52 Week High | $73.70 | $73.51 |
| Indicator | GIL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 62.58 | 72.31 |
| Support Level | $71.08 | $59.38 |
| Resistance Level | $73.70 | $63.75 |
| Average True Range (ATR) | 1.65 | 1.93 |
| MACD | -0.03 | 0.55 |
| Stochastic Oscillator | 74.14 | 94.59 |
Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. Its primary market is the sale of blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels. Brands include Gildan, American Apparel, Comfort Colors, and Goldtoe. Gildan produces most of its clothing at factories in Latin America but has been ramping up production at its new facility in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generates nearly 90% of its sales in the US. Gildan is acquiring its US rival Hanesbrands to bolster its consumer and printwear operations.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.